1. 18TiPDESIGN OF A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN (SGN-35) AS SALVAGE THERAPY FOR MALES WITH CHEMORESISTANT GERM-CELL TUMORS (GCT). (November 2014) Authors: Giannatempo, P.; Anichini, A.; Raggi, D.; Cordareschi, E.; Nicolai, N.; Colecchia, M.; Salvioni, R.; Valagussa, P.; Gianni, A.; Necchi, A. Journal: Annals of oncology Issue: Volume 25(2014)Supplement 6 Page Start: vi6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). (September 2015) Authors: Rosenberg, J.; Petrylak, D.; Abidoye, O.; Van der Heijden, M.S.; Hofman-Censits, J.; Necchi, A.; O'Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; Retz, M.; Perez-Gracia, J.L.; Dawson, N.A.; Balar, A.; Galsky, M.D.; Fleming, M.T.; Powles, T.; Cui, N.; Mariathasan, S.; Fine, G.D.; Dreicer, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S720 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2607 Predicting venous thromboembolism (VTE) in metastatic urothelial tract tumors (UTT). (September 2015) Authors: Ramos, J.; Casey, M.; Bamias, A.; De Giorgi, U.; Bellmunt, J.; Harshman, L.; Ladoire, S.; Wong, Y.N.; Alva, A.; Necchi, A.; Recine, F.; Vaishampayan, U.; Niegisch, G.; Pal, S.; Crabb, S.; Golshayan, A.; Srinivas, S.; Rosenberg, J.; Galsky, M.; Yu, E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). (September 2015) Authors: Harshman, L.; Werner, L.; Wong, Y.N.; Yu, E.; Alva, A.; Crabb, S.; Powles, T.; Rosenberg, J.; Baniel, J.; Vaishampayan, U.; Berthold, D.; Ladoire, S.; Hussain, S.; Milowsky, M.; Agarwal, N.; Necchi, A.; Pal, S.; Recine, F.; Bellmunt, J.; Galsky, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S518 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 2639 Effectiveness and possible Molecular factors predictive of clinical Outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: A multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). (September 2015) Authors: Passalacqua, R.; Montironi, R.; Lazzarelli, S.; Donini, M.; Perrucci, B.; Nolè, F.; Ceresoli, G.L.; Pignata, S.; Torricelli, F.; Giannatempo, P.; Doni, L.; Ungari, M.; Panni, S.; Necchi, A.; Betri, E.; De Giorgi, U.; Sabbatini, R.; Rondini, E.; Sequino, M.; Caminiti, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S526 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 2643 Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (UBC): Updated clinical and translational findings of an open-label, single group, phase 2 study. (September 2015) Authors: Necchi, A.; Giannatempo, P.; Mariani, L.; Raggi, D.; Nicolai, N.; Piva, L.; Biasoni, D.; Catanzaro, M.; Torelli, T.; Stagni, S.; Calareso, G.; Togliardi, E.; Colecchia, M.; Busico, A.; Perrone, F.; Pelosi, G.; Maffezzini, M.; Salvioni, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinical significance of early circulating tumor cells (CTC) changes, analyzed by AdnaTest, in patients (pts) receiving first-line methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy (CT) for metastatic urothelial cancer (UC). (December 2016) Authors: Necchi, A.; Fina, E.; Giannatempo, P.; Colecchia, M.; Raggi, D.; Daidone, M.G.; Cappelletti, V. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Molecular profiling of post-pembrolizumab muscle-invasive bladder cancer reveals unique features that may inspire new sequential therapies in nonresponders. (October 2020) Authors: Marandino, L.; de Jong, J.J.; Raggi, D.; Gallina, A.; Bandini, M.; Giannatempo, P.; Colecchia, M.; Briganti, A.; Montorsi, F.; Davicioni, E.; Seiler, R.; Black, P.; Gibb, E.A.; Necchi, A. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study. (February 2017) Authors: Necchi, A.; Bellmunt, J.; De Wit, R.; Vaughn, D.; Fradet, Y.; Lee, J.L.; Fong, L.; Vogelzang, N.; Climent, M.; Petrylak, D.; Choueiri, T.; Gerritsen, W.; Gurney, H.; Quinn, D.; Culine, S.; Sternberg, C.; Mai, Y.; Puhlmann, M.; Perini, R.; Bajorin, D. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗